Skip to Main Content

Puma Biotechnology (PBYI) has a European problem.

Scientific advisers attached to the European Medicines Agency (EMA) issued a “negative trend vote” Tuesday on Puma’s breast cancer drug Nerlynx — an indication they’d be unwilling to issue a recommendation favoring approval.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!